466 F.Supp. 100 (D.N.J. 1979), Cir. A. 78-2792, Pharmadyne Laboratories, Inc. v. Kennedy
Linked as:
Extract
466 F.Supp. 100 (D.N.J. 1979), Cir. A. 78-2792, Pharmadyne Laboratories, Inc. v. Kennedy
No longer available (Autolink)
See the full content of this document
This document cites
- Code of Federal Regulations - Scope of this part
- Code of Federal Regulations - Definitions
- Code of Federal Regulations - Requirements for submission of bioavailability and bioequivalence data
- Code of Federal Regulations - Criteria for waiver of evidence of in vivo bioavailability or bioequivalence
- US Code - 21 U.S.C. § 321 Definitions; Generally
